Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bizalimogene ralaplasmid
- Development stage
- Phase 3
- Lead developer
- Inovio Pharmaceuticals
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Bizalimogene ralaplasmid is a DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papillomavirus (HPV) subtypes 16 and 18. It is designed to elicit an immune response against cells expressing these HPV oncogenes, thereby providing immunostimulatory and antineoplastic effects. The drug is being developed primarily for the treatment of pre-cancers and cancers associated with HPV infection, such as cervical intraepithelial neoplasia (CIN) and anal intraepithelial neoplasia. Its mechanism involves stimulating the immune system to target HPV-infected or transformed cells[1][3][8]. The primary developer is Inovio Pharmaceuticals, with involvement from ApolloBio and AIDS Malignancy Consortium. The originator institution is University of Pennsylvania[3].
- Brand names
- VGX-3100VGX3100VGX 3100
- Other names
- Human papillomavirus vaccine-VGX Pharmaceuticals
02
Targets
HPV16 E7 (Human papillomavirus 16 E7 protein)HPV16 E6 oncoproteinHPV18 E7
Beyond the preview
Go deeper on bizalimogene ralaplasmid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bizalimogene ralaplasmid.